Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Conditions: Advanced Solid Tumor; CDKN2A; NSCLC; Urothelial Carcinoma Bladder; Melanoma; Pancreas Adenocarcinoma; HNSCC; Renal Cell Carcinoma; Mesothelioma; Gastric Cancer Interventions: Drug: Milademetan; Drug: Atezolizumab Sponsors: Rain Oncology Inc Withdrawn
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Asbestosis | Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Gastric (Stomach) Cancer | Gastroenterology | HNSCC | Kidney Cancer | Melanoma | Mesothelioma | Non-Small Cell Lung Cancer | Pancreas | Pancreatic Cancer | Renal Cell Carcinoma | Research | Skin Cancer